INmune Bio Q2 net loss $6.5M; XPro™ AD trial enrolling; INKmune™ IND cleared

Inmune Bio, Inc.

2023-Q2 EPS reported -$0.73 revenue$84,000

Net loss $6.5M vs $6.8M YoY; R&D $4.1M; G&A $2.3M; cash $47.8M at June 30, 2023.
XPro™ Phase II Early AD trial enrolling; FDA pathway to lift clinical hold before end-2023.
New MRI gray matter biomarker data from XPro™ presented at AAIC July 2023.
INKmune™ IND cleared for Phase I/II in mCRPC; first patient enrollment expected Q4 2023.
Top-line XPro™ AD results anticipated late 2024; LAUREL trial opened third site in Greece.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

Inmune Bio, Inc. reported financial results for quarter ended June 30, 2023.

Period: quarter ended June 30, 2023
Result: reported results

Exact text from the filing

On August 7, 2023, INmune Bio Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2023

View on SEC.gov

Browse all earnings releases →

Inmune Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-23-064516

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.